Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $105.00. They now have an "overweight" rating on the stock.
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Guggenheim.
Structure Therapeutics (NASDAQ:GPCR) was given a new $102.00 price target on by analysts at The Goldman Sachs Group, Inc..